PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB24FD3F84565524810!beyfortus 50 MG 0.5 ML syringe 0.5ml — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB20D1100. PoP ended Aug 20, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Amerisourcebergen Drug Corp

Recipient

Aug 20, 2024

PoP end

$462K

Obligated

$462K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal

Contract numberSPE2DB24FD3F8

Also listed asSPE2DB20D1100-SPE2DB24FD3F8

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentAmerisourcebergen Drug Corp

CAGE1XUY5

UEIKABZK8W6PQT3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DB20D1100

Place of performanceCONSHOHOCKEN PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startAug 19, 2024

PoP end (current)Aug 20, 2024

Obligated$462K

Current value$462K

Potential value$462K

4565524810!BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $462K ($462K obligated). Current period of performance ends Aug 20, 2024. Place of performance: CONSHOHOCKEN PA.

4565524810!BEYFORTUS 50 MG/0.5 ML SYRINGE 0.5ML

Recompete timing

Public

● Past PoP end (731 days ago)

Current PoP ended Aug 20, 2024 (731 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies

Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C77026P0121

DROSPIRENONE

$321K

Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DB24FD3F8?

SPE2DB24FD3F8 (4565524810!beyfortus 50 MG 0.5 ML syringe 0.5ml) is a Dla Troop Support award with a potential value of $462K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB24FD3F8?

Dla Troop Support awarded SPE2DB24FD3F8 to Amerisourcebergen Drug Corp (potential $462K).

Who is the incumbent on SPE2DB24FD3F8?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Aug 20, 2024.

When does Amerisourcebergen Drug Corp’s SPE2DB24FD3F8 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 20, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 11, 2026 · refreshed monthlyLatest procurement action Aug 19, 2024